Cargando…

Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques

OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Haycroft, Ebene R, Damelang, Timon, Lopez, Ester, Rodgers, Mark A, Wines, Bruce D, Hogarth, Mark, Ameel, Cassaundra L, Kent, Stephen J, Scanga, Charles A, O'Connor, Shelby L, Chung, Amy W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660403/
https://www.ncbi.nlm.nih.gov/pubmed/38020728
http://dx.doi.org/10.1002/cti2.1474
_version_ 1785148402415173632
author Haycroft, Ebene R
Damelang, Timon
Lopez, Ester
Rodgers, Mark A
Wines, Bruce D
Hogarth, Mark
Ameel, Cassaundra L
Kent, Stephen J
Scanga, Charles A
O'Connor, Shelby L
Chung, Amy W
author_facet Haycroft, Ebene R
Damelang, Timon
Lopez, Ester
Rodgers, Mark A
Wines, Bruce D
Hogarth, Mark
Ameel, Cassaundra L
Kent, Stephen J
Scanga, Charles A
O'Connor, Shelby L
Chung, Amy W
author_sort Haycroft, Ebene R
collection PubMed
description OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS: Here, we used a simian immunodeficiency virus (SIV)/TB‐coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV‐negative (n = 8) and SIV‐positive (n = 7) MCM 8‐week postinfection with Mycobacterium tuberculosis (Mtb). RESULTS: Antibody responses to Mtb were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8‐week post‐Mtb infection, including increased agalactosylation (G0) and reduced di‐galactosylation (G2), which correlated with endpoint Mtb bacterial burden and gross pathology scores, as well as the time‐to‐necropsy. CONCLUSION: These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression.
format Online
Article
Text
id pubmed-10660403
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106604032023-11-20 Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques Haycroft, Ebene R Damelang, Timon Lopez, Ester Rodgers, Mark A Wines, Bruce D Hogarth, Mark Ameel, Cassaundra L Kent, Stephen J Scanga, Charles A O'Connor, Shelby L Chung, Amy W Clin Transl Immunology Short Communication OBJECTIVES: Tuberculosis (TB) remains a substantial cause of morbidity and mortality among people living with human immunodeficiency virus (HIV) worldwide. However, the immunological mechanisms associated with the enhanced susceptibility among HIV‐positive individuals remain largely unknown. METHODS: Here, we used a simian immunodeficiency virus (SIV)/TB‐coinfection Mauritian cynomolgus macaque (MCM) model to examine humoral responses from the plasma of SIV‐negative (n = 8) and SIV‐positive (n = 7) MCM 8‐week postinfection with Mycobacterium tuberculosis (Mtb). RESULTS: Antibody responses to Mtb were impaired during SIV coinfection. Elevated inflammatory bulk IgG antibody glycosylation patterns were observed in coinfected macaques early at 8‐week post‐Mtb infection, including increased agalactosylation (G0) and reduced di‐galactosylation (G2), which correlated with endpoint Mtb bacterial burden and gross pathology scores, as well as the time‐to‐necropsy. CONCLUSION: These studies suggest that humoral immunity may contribute to control of TB disease and support growing literature that highlights antibody Fc glycosylation as a biomarker of TB disease progression. John Wiley and Sons Inc. 2023-11-20 /pmc/articles/PMC10660403/ /pubmed/38020728 http://dx.doi.org/10.1002/cti2.1474 Text en © 2023 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Haycroft, Ebene R
Damelang, Timon
Lopez, Ester
Rodgers, Mark A
Wines, Bruce D
Hogarth, Mark
Ameel, Cassaundra L
Kent, Stephen J
Scanga, Charles A
O'Connor, Shelby L
Chung, Amy W
Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title_full Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title_fullStr Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title_full_unstemmed Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title_short Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
title_sort antibody glycosylation correlates with disease progression in siv‐ mycobacterium tuberculosis coinfected cynomolgus macaques
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660403/
https://www.ncbi.nlm.nih.gov/pubmed/38020728
http://dx.doi.org/10.1002/cti2.1474
work_keys_str_mv AT haycroftebener antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT damelangtimon antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT lopezester antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT rodgersmarka antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT winesbruced antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT hogarthmark antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT ameelcassaundral antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT kentstephenj antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT scangacharlesa antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT oconnorshelbyl antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques
AT chungamyw antibodyglycosylationcorrelateswithdiseaseprogressioninsivmycobacteriumtuberculosiscoinfectedcynomolgusmacaques